Objective: To explore the infection rate of HBV of Yao population in Ruyuan and the correction between Hepatitis B virus genotypes and clinical disease spectra. Methods: ELISA was used to detect hepatitis B virus markers of 665 Yao population and 589 Han population. And microboard nucleate molecular hybridization ELISA was used to detect the genotype of 97 cases of different clinical types of HBV infections. Results: HBsAg positive rate of Yao population (20.3%) was higher than Han population (13.4%), and significance difference was found in males (25.81% vs 13.22%, P < 0.05). Among the 97 HBV patients of Yao population, genotype B took up the largest proportion (52.58%, 51/97), followed by genotype C (36.08%, 35/97), and then 7 cases of mixed genotype (4 cases of B/C, 3 cases of C/D). No genotype E or F was detected. Genotype B was higher than genotype C (52.94% vs 25.71%, p < 0.05) in asymptomatic carriers, while genotype C was higher than genotype B (62.85% vs 27.45%, p < 0.05) in mild or moderate chronic hepatitis B. Conclusion: HBsAg positive rate of males in Ruyuan of Yao population was higher than that of Han population. Genotype B was the main type in this area, followed by genotype C.
Objective: To evaluate to set ambiguous region of screening HBsAg ELISA results whether improving blood safety by HBsAg confirmatory assay and super-sensitivity screening kits. Method: The samples, which HBsAg screening results were in ambiguous region, were retested by HBsAg confirmatory assay using hepatitis B immunoglobulin and super-sensitivity screening kits. Results: The 21 samples were positive tested by HBsAg super-sensitivity screening kits, in which 15 samples were positive confirmed by HBsAg confirmatory assay and other 6 samples were false positive. The average S/CO value of negative samples, which retested by HBsAg super-sensitivity screening kits, was not significance rise compared with other two routine HBsAg screening kits in our laboratory. Conclusion: Setting ambiguous region of screening HBsAg ELISA in Chinese blood donations improved blood safety and prevented HBsAg screening failure.
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Aim: To study was to investigate the genotypic prevalence and clinical significance of HCV, HBV, and/or HDV among chronic hepatitis patients with and without liver cirrhosis and/or HCC in Tajikistan. Methods: Sera were obtained from 124 consecutive cases of chronic liver diseases. Patients in this study were classified into two clinical groups: (i) chronic hepatitis and (ii) liver cirrhosis. Results: Genotypes of HBV, HCV, and HDV were determined by genetic sequencing. The overall prevalence of anti-HCV, HCV core antigen (HCVcAg) and HBsAg was 46% (57/124) and 41.1% (51/124), respectively. Co-infection of HCV/HBV, HBV/HDV, and HCV/HBV/HDV was found in 4.8% (6/124), 11.2% (12/124), and 0.8% (1/124) of cases, respectively. HDV genotype 1 was found in 19.6% (10/51) of HBsAgpositive patients. The HBV/HDV co-infection was relatively high in group 2 compared with group 1 (15% vs. 7.1%). HCV/1b was detected in 84.6% (44/52) of HCV RNA-positive patients, followed by 3a (7.6%), 2a (5.7%), and 2c (1.9%). HBV/D was detected in 94.1% (48/51) of HBsAg-positive patients, followed by HBV/A [5.8% (3/51)]. T1762/A1764 double mutation was associated with liver cirrhosis in HBVinfected patients (P = 0.0004). Conclusion: Among HBV-infected patients, the T1762/A1764 mutation was associated with liver cirrhosis. Background: The progressing increasing of hypoxia inducible factor-1alpha (HIF-1a) and HIF-1amRNA were found during the malignant transformation of hepatocytes in our previous work. In this study, the expression of hepatic HIF-1a and level of its gene transcription were investigated in different tissues of human hepatocellular carcinoma (HCC) for exploring the relationship between HIF-1a expression and HCC development. Background: Hepatocellular carcinoma (HCC) prognosis is poor and early diagnosis is of the utmost importance. The objective of this study was to investigate the dynamic expression of glypican-3 (GPC-3) and its gene in hepatocarcinogenesis, the relationship of its expression with HBV infection, and diagnostic values for HCC. Methods: The characteristics of GPC-3 expression were observed by rat hepatoma models. Liver GPC-3 Expression was analyzed by immunohisto-chemistry or Western blotting. Hepatic GPC-3 mRNAs were extracted and amplified by using a nested polymerase chain reaction (PCR) or real-time PCR assay. The amplified fragments of GPC-3 gene were confirmed by DNA sequencing. The level of serum GPC-3 in patients with liver diseases was quantitatively detected by an ELISA method.
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Results: The dynamic alteration of GPC-3 was confirmed by hepatoma models with brown granule-like staining localized in membrane and cytoplasm in morphological stages of granule-like degeneration, atypical hyperplasia and cancer formation. Of self-control human HCC tissues, the incidence of GPC-3 was 80.6% in HCC, 41.7% in their surrounding, and none in distant group (c 2 = 11.445, P < 0.000) with no significant relationship between GPC-3 and differentiation grade or tumor number except of tumor size (Z = 2.941, P = 0.003); and the features of circulating GPC-3 was detected in only HCC patients (52.8%) without significant different between GPC-3 and sex, age, AFP, tumor number, Child-pugh classification or extrahepatic metastasis except of size (c 2 = 6.318, P = 0.012) and HBV infection (c 2 = 23.362, P < 0.000). Combined analysis of GPC-3 and AFP levels could rise up to 87% for HCC diagnosis.
Conclusions: Abnormal expression of hepatic and circulating GPC-3 may be associated closely with occurrence of HCC and could be a useful specific molecular marker for HCC diagnosis. Background: Chronic hepatitis B (CHB) is a severe liver disease and can progressively develop hepatic fibrosis. Notably, high levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) expression are observed in patients with liver fibrosis. However, the potential relationship between the levels of serum TIMP-1, hepatic TIMP-1, and the degrees of hepatic fibrosis in patients with CHB has not yet been illustrated. This study aimed at investigating the relationship between TIMP-1 expression and liver fibrosis severity in patients with CHB.
Methods: In the present study, a total of 159 CHB with varying degrees of liver fibrosis were recruited and subjected to liver biopsy for the analysis of their liver fibrotic stages and inflammatory activities. The levels of TIMP-1 expression in the liver tissues and serum TIMP-1 in those patients were determined by immunohistochemistry and enzyme-linked immunoabsorbent assay (ELISA), respectively. Results: Our results indicated that the concentrations of serum TIMP were positively correlated with the levels of TIMP-1 expression in the liver tissues (R = 0.9521) and the degrees of liver fibrosis (0.704) in CHB patients with inflammation at grade 2. More importantly, the concentrations of serum TIMP-1 were independent of the degrees of inflammation in those patients. Conclusion: Our findings suggest that the TIMP-1 may be a valuable biomarker, and that the detection of serum TIMP-1 concentrations may be a safe and cost-effective measure for the evaluation of liver fibrosis at least in CHB patients.
